Pathogenesis of group a streptococcal infections and their sequelae

Advances in Experimental Medicine and Biology

Volumn 609, Issue , 2008, Pages 29-42

  Cunningham, Madeleine W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

M PROTEIN; STREPTOCOCCUS VACCINE;

ALLERGIC GLOMERULONEPHRITIS; ANTIGEN ANTIBODY REACTION; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHOREA MINOR; CONFERENCE PAPER; ENDOTHELIUM; GROUP A STREPTOCOCCAL INFECTION; HEART VALVE; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; INFECTION SENSITIVITY; LYMPHOCYTIC INFILTRATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATIC FEVER; RHEUMATIC HEART DISEASE; STREPTOCOCCUS GROUP A; CHOREA; GLOMERULONEPHRITIS; IMMUNOLOGY; MICROBIOLOGY; PATHOGENICITY; PATHOPHYSIOLOGY; REVIEW; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES; T LYMPHOCYTE;

CHOREA; GLOMERULONEPHRITIS; HOST-PATHOGEN INTERACTIONS; HUMANS; RHEUMATIC FEVER; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; T-LYMPHOCYTES;

EID: 39149099801     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-73960-1_3     Document Type: Conference Paper

References (90)

1. Beall B, Facklam R, and Thompson T. (1996). Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci. J Clin Microbiol, 34:953-958.
2. Bessen D and Fischetti VA. (1988a). Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci. Infect Immun, 56:2666-2672.
3. Bessen D and Fischetti VA. (1988b). Passive acquired mucosal immunity to group A streptococci by secretory immunoglobulin A. J Exp Med, 167:1945-1950.
4. Bessen D and Fischetti VA. (1988c). Role of Non-Opsonic Antibody in Protection Against Group A Streptococcal Infection. Alan R Liss, New York, NY.
5. Bessen D and Fischetti VA. (1990). Synthetic peptide vaccine against mucosal colonization by group A streptococci. I. Protection against a heterologous M serotype with shared C repeat region epitopes. J Immunol, 145:1251-1256.
6. Bessen DE and Fischetti VA. (1997). Vaccines against Streptococcus pyogenes infections. Marcel Decker, Inc, New York, NY.
7. Bessen DE, Veasy LG, Hill HR, Augustine NH, and Fischetti VA. (1995). Serologic evidence for a class I group A streptococcal infection among rheumatic fever patients. J Infect Dis, 172:1608-1611.
8. Bessen DE, Sotir CM, Readdy TL, and Hollingshead SK. (1996). Genetic correlates of throat and skin isolates of group A streptococci. J Infect Dis, 173:896-900.
9. Bessen D, Beall B, and Hollingshead S. (1998). Presented at the ASM Conference on Streptococcal Genetics: Genetics of the Streptococci, Enterococci, and Lactococci. Vichy, France.
10. Bessen DE, Carapetis JR, Beall B, Katz R, Hibble M, Currie BJ, Collingridge T, Izzo MW, Scaramuzzino DA, and Sriprakash KS. (2000). Contrasting molecular epidemiology of group A streptococci causing tropical and nontropical infections of the skin and throat. J Infect Dis, 182:1109-1116.
11. Bisno AL. (1995a). Non-suppurative poststreptococcal sequelae: rheumatic fever and glomeru-lonephritis. In Mandell GL, Bennett JE, and Dolin R (eds.), Principles and Practice of Infectious Diseases, Vol. 2. Churchill Livingstone, New York, NY, pp. 1799-1810.
12. Bisno AL. (1995b). Streptococcus Pyogenes. In Mandell GL, Bennett RG, and Dolin R (eds.), Principles and Practice of Infectious Diseases, Vol. 2. Churchill Livingstone, New York, NY, pp. 1786-1799.
13. Bisno AL, Brito MO, and Collins CM. (2003). Molecular basis of group A streptococcal virulence. Lancet Infect Dis, 3:191-200.
14. Chatellier S, Ihendyane N, Kansal RG, Khambaty F, Basma H, Norrby-Teglund A, Low DE, McGeer A, and Kotb M. (2000). Genetic relatedness and superantigen expression in group A streptococcus serotype Ml isolates from patients with severe and nonsevere invasive diseases. Infect Immun, 68:3523-3534.
15. Cleary P, Prabu U, Dale J, Wexler D, and Handley J. (1992). Streptococcal C5a peptidase is a highly specific endopeptidase. Infect Immun, 60:5219-5223.
16. Courtney HS, Hasty DL, and Dale JB. (2002). Molecular mechanisms of adhesion, colonization, and invasion of group A streptococci. Ann Med, 34:77-87.
17. Cunningham MW. (2000). Pathogenesis of group A Streptococcal Infections. Clin Microbiol Rev, 13:470-511.
18. Cunningham MW, McCormack JM, Talaber LR, Harley JB, Ayoub EM, Muneer RS, Chun LT, and Reddy DV (1988). Human monoclonal antibodies reactive with antigens of the group A Streptococcus and human heart. J Immunol, 141:2760-2766.
19. Cunningham MW, McCormack JM, Fenderson PG, Ho MK, Beachey EH, and Dale JB. (1989). Human and murine antibodies cross-reactive with streptococcal M protein and myosin recognize the sequence GLN-LYS-SER-LYS-GLN in M protein. J Immunol, 143:2677-2683.
20. Cunningham MW, Antone SM, Smart M, Liu R, and Kosanke S. (1997). Molecular analysis of human cardiac myosin-cross-reactive B- and T-cell epitopes of the group A streptococcal M5 protein. Infect Immun, 65:3913-3923.
21. Dajani AS. (1992). Guidelines for the diagnosis of rheumatic fever (Jones criteria, 1992 update). J Am Med Assoc, 268:2069-2073.
22. Dajani AS, Bisno AL, Chung KJ, Durack DT, Gerber MA, Kaplan EL, Millard HD, Randolph MF, Shulman ST, and Watanakunakorn C. (1989). Prevention of rheumatic fever: a statement for health professionals by the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease of the Council on Cardiovascular Disease in the young, the American Heart Association. Pediatr Infect Dis, 8:263-266.
23. Dale JB. (1999). Multivalent group A streptococcal vaccine designed to optimize the immuno-genicity of six tandem M protein fragments. Vaccine, 17:193-200.
24. Dale JB, Washburn RG, Marques MB, and Wessels MR. (1996). Hyaluronate capsule and surface M protein in resistance to opsonization of group A streptococci. Infect Immun, 64:1495-1501.
25. Dudding BA and Ayoub EM. (1968). Persistence of streptococcal group A antibody in patients with rheumatic valvular disease. J Exp Med, 128:1081.
26. Ellis NMJ, Li Y, Hildebrand W., Fischetti VA, and Cunningham MW. (2005). T cell mimicry and epitope specificity of crossreactive T cell clones from rheumatic heart disease. J Immunol, 175:5448-5456.
27. Fae KC, da Silva DD, Oshiro SE, Tanaka AC, Pomerantzeff PM, Douay C, Charron D, Toubert A, Cunningham MW, Kalil J, and Guilherme L. (2006). Mimicry in recognition of cardiac myosin peptides by heart-intralesional T cell clones from rheumatic heart disease. J Immunol, 176:5662-5670.
28. Fischetti VA. (1989). Streptococcal M protein: molecular design and biological behavior. Clin Microbiol Rev, 2:285-314.
29. Fischetti VA. (1991). Streptococcal M protein. Sci Am, June issue:58-65.
30. Galvin JE, Hemric ME, Ward K, and Cunningham MW. (2000). Cytotoxic monoclonal antibody from rheumatic carditis reacts with human endothelium: implications in rheumatic heart disease. J Clin Invest, 106:217-224.
31. Garvey MA and Swedo SE. (1997). Sydenham's chorea. Clinical and therapeutic update. Adv Exp Med Biol, 418:115-120.
32. Gerlach D, Schmidt KH, and Fleischer B. (2001). Basic streptococcal superantigens (SPEX/SMEZ or SPEC) are responsible for the mitogenic activity of the so-called mitogenic factor (MF). FEMS Immunol Med Microbiol, 30:209-216.
33. Giannakis E, Jokiranta TS, Ormsby RJ, Duthy TG, Male DA, Christiansen D, Fischetti VA, Bagley C, Loveland BE, and Gordon DL. (2002). Identification of the streptococcal M protein binding site on membrane cofactor protein (CD46). J Immunol, 168:4585-592.
34. Gibofsky A, Kerwar S, and Zabriskie JB. (1998). Rheumatic fever: the relationships between host, microbe and genetics, 24(2):237-259.
35. Guedez Y, Kotby A, El-Demellawy M, Galal A, Thomson G, Zaher S, Kassen S, and Kotb M. (1999). HLA class II associations with rheumatic heart disease are more evident and consistent among clinically homogeneous patients. Ciculation, 99:2784-2790.
36. Guilherme L, Cunha-Neto E, Coelho V, Snitcowsky R, Pomerantzeff PMA, Assis RV, Pedra F, Neumann J, Goldberg A, Patarroyo ME, Pileggi F, and Kalil J. (1995). Human heart-filtrating T cell clones from rheumatic heart disease patients recognize both streptococcal and cardiac proteins. Circulation, 92:415-20.
37. Guilherme L, Cury P, Demarchi LMF, Abel L, Lopez AP, Oshiro SE, Aliotti S, Cunha-Neto E, Pomerantzeff PMA, Tanaka AC, and Kalil J. (2004). Rheumatic heart disease: proinflammatory cytokines play a role in the progression and maintenance of valvular lesions. Am J Pathol, 165:1583-1591.
38. Hasty DL and Courtney HS. (1996). Group A Streptococcal Adhesion: All of the Theories are Correct. Plenum Press, New York, NY.
39. Hasty DL, Ofek I, Courtney HS, and Doyle RJ. (1992). Multiple adhesins of streptococci. Infect Immun, 60:2147-2152.
40. Herwald H, Cramer H, Morgelin M, Russell W, Sollenberg U, Norrby-Teglund A, Flodgaard H, Lindbom L, and Bjorck L. (2004). M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. Cell, 116:367-379.
41. Herwald H, Morgelin M, Dahlback B, and Bjorck L. (2003). Interactions between surface proteins of Streptococcus pyogenes and coagulation factors modulate clotting of human plasma. J Thromb Haemost, 1:284-291.
42. Horstman RD, Jurgen Sievertsen H, Knobloch J, and Fischetti VA. (1988). Antiphagocytic activity of streptococcal M protein: Selective binding of complement control protein factor H. Proc Natl Acad Sci U S A, 85:1657-1661.
43. Huber SA and Cunningham MW. (1996). Streptococcal M protein peptide with similarity to myosin induces CD4+ T cell-dependent myocarditis in MRL/++ mice and induces partial tolerance against coxsakieviral myocarditis. J Immunol, 156:3528-3534.
44. Husby G, van de Rijn I, Zabriskie JB, Abdin ZH, and Williams RC. (1976). Antibodies reacting with cytoplasm of subthalamic and caudate nuclei neurons in chorea and acute rheumatic fever. J Exp Med, 144:1094-1110.
45. Jarva H, Jokiranta TS, Wurzner R, and Meri S. (2003). Complement resistance mechanisms of streptococci. Mol Immunol, 40:95-107.
46. Ji Y, McLands borough L, Kondagunta A, and Cleary PR (1996). C5a peptidase alters clearance and trafficking of group A streptococci by infected mice. Infect Immun, 64:503-510.
47. Ji Y, Carlson B, Kondagunta A, and Cleary PR (1997). Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A streptococcus. Infect Immun, 65:2080-2087.
48. Jones TD. (1944). The diagnosis of rheumatic fever. J Am Med Assoc, 126:481-84.
49. Kaplan EL. (2004). Rheumatic heart disease in rural Pakistan. Heart, 90:361-362.
50. Kaplan MH and Dallenbach FD. (1961). Immunologic studies of heart tissue. II. Occurrence of bound gamma-globulin in auricular appendages from rheumatic hearts. Relationship to certain histopathologic features of rheumatic heart disease. J Exp Med, 113:1-16.
51. Kaplan MH, Bolande R, Rakita L, and Blair J. (1964). Presence of bound immunoglobulins and complement in the myocardium in acute rheumatic fever. Association with cardiac failure. N Engl J Med, 271:637-645.
52. Kazmi SU, Kansal R, Aziz RK, Hooshdaran M, Norrby-Teglund A, Low DE, Halim AB, and Kotb M. (2001). Reciprocal, temporal expression of SpeA and SpeB by invasive M1T1 group a streptococcal isolates in vivo. Infect Immun, 69:4988-995.
53. Kirvan CA, Swedo SE, Heuser S, and Cunningham MW. (2003). Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nat Med, 9:914-920.
54. Kotarsky H, Gustafsson M, Svensson HG, Zipfel PF, Truedsson L, and Sjobring U. (2001). Group A streptococcal phagocytosis resistance is independent of complement factor H and factor H-like protein 1 binding. Mol Microbiol, 41:817-826.
55. Kotb M. (1995). Bacterial pyrogenic exotoxins as superantigens. Clin Microbiol Rev, 8:411-426.
56. Kotb M, Norrby-Teglund A, McGeer A, El-Sherbini H, Dorak MT, Khurshid A, Green K, Peeples J, Wade J, Thomson G, Schwartz B, and Low DE. (2002). An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat Med, 8:1398-1404.
57. Krisher K and Cunningham MW. (1985). Myosin: a link between streptococci and heart. Science, 227:413-415.
58. Massell BF. (1997). Rheumatic fever and streptococcal infection: unraveling the mysteries of a dread disease. Harvard University Press for The Francis A. Countway Library of Medicine, Boston, MA.
59. McCarty M. (1956). Variation in the group specific carbohydrates of group A streptococci. II. Studies on the chemical basis for serological specificity of the carbohydrates. J Exp Med, 104:629-643.
60. Muller-Alouf H, Proft T, Zollner TM, Gerlach D, Champagne E, Desreumaux P, Fitting C, Geoffroy-Fauvet C, Alouf JE, and Cavaillon JM. (2001). Pyrogenicity and cytokine-inducing properties of Streptococcus pyogenes superantigens: comparative study of streptococcal mitogenic exotoxin Z and pyrogenic exotoxin A. Infect Immun, 69:4141-4145.
61. Okada N, Pentland AP., Falk P, and Caparon MG. (1994). M protein and protein F act as important determinants of cell-specific tropism of Streptococcus pyogenes in skin tissue. J Clin Invest, 94:965-977.
62. Okada N, Liszewski M, Atkinson J, and Caparon M. (1995). Membrane cofactor protein (CD46) is a keratinocyte receptor for the M protein of the group A streptococcus. Proc Natl Acad Sci, 92:2489-2493.
63. Pancholi V and Fischetti VA. (1988). Isolation and characterization of the cell-associated region of group A streptococcal M6 protein. J Bacteriol, 170:2618-2624.
64. Proft T, Moffatt SL, Weller KD, Paterson A, Martin D, and Fraser JD. (2000). The streptococcal superantigen SMEZ exhibits wide allelic variation, mosaic structure, and significant antigenic variation. J Exp Med, 191:1765-1776.
65. Proft T, Webb PD, Handley V, and Fraser JD. (2003). Two novel superantigens found in both group A and group C Streptococcus. Infect Immun, 71:1361-1369.
66. Quinn A, Kosanke S, Fischetti VA, Factor SM, and unningham MW. (2001). Induction of autoimmune valvular heart disease by recombinant streptococcal M protein. Infect Immun, 69:4072-4078.
67. Roberts S, Kosanke S, Dunn ST, Jankelow D, Duran CMG, and Cunningham MW. (2001). Immune mechanisms in rheumatic carditis: Focus on valvular endothelium. J Infect Dis, 183:507-511.
68. Shet A, Kaplan EL, Johnson DR, and Cleary PP. (2003). Immune response to group A streptococcal C5a peptidase in children: implications for vaccine development. J Infect Dis, 188:809-817.
69. Silva FG. (1998). Acute Postinfectious Glomerulonephritis and Glomerulonephritis Complicating Persistent Bacterial Infection, 5th edn. Lippincott-Raven Publishers, Philadelphia, PA.
70. Stevens DL. (2000). Streptococcal toxic shock syndrome associated with necrotizing fasciitis. Annu Rev Med, 51:271-288.
71. Stollerman GH. (1975). Rheumatic Fever and Streptococcal Infection. Grune and Stratum, New York, NY.
72. Stollerman GH. (1988). Rheumatic and heritable connective tissue diseases of the cardiovascular system. In Braunmald E (ed.), Heart Disease: A Textbook of Cardiovascular Medicine, Vol. 11. W.B. Saunders, Philadelphia, PA, pp. 1706-1734.
73. Stollerman GH. (1997). Rheumatic fever. Lancet, 349:935-942.
74. Swedo SE. (1994). Sydenham's chorea: a model for childhood autoimmune neuropsychiatric disorders. J Am Med Assoc, 272:1788-1791.
75. Swedo SE, Leonard HL, Schapiro MB, Casey BJ, Mannheim GB, Lenane MC, and Rettew DC. (1993). Sydenham's chorea: physical and psychological symptoms of St. Vitus dance. Pediatrics, 91:706-713.
76. Taranta A, Torosdag S, and Metrakos JD. (1959). Rheumatic fever in monozygotic and dizygotic twins. Circulation, 20:778-792.
77. Unnikrishnan M, Altmann DM, Proft T, Wahid F, Cohen J, Fraser JD, and Sriskandan S. (2002). The bacterial superantigen streptococcal mitogenic exotoxin Z is the major immunoactive agent of Streptococcus pyogenes. J Immunol, 169:2561-2569.
78. Veasy LG. (1995). Rheumatic fever-T. Duckett Jones and the rest of the story. Cardiol Young, 5:293-301.
79. Veasy LG. (2001). Time to take soundings in acute rheumatic fever. Lancet, 357:1994-1995.
80. Veasy LG, Wiedmeier SE, and Orsmond GS. (1987). Resurgence of acute rheumatic fever in the intermountain area of the United States. N Engl J Med, 316:421-427.
81. Veasy LG, Tani LY, and Hill HR. (1994). Persistence of acute rheumatic fever in the intermountain area of the United States. J Pediatr, 124:9-16.
82. Veasy LG, Tani LY, Daly JA, Korgenski K, Miner L, Bale J, Kaplan EL, Musser JM, and Hill HR. (2004). Temporal association of the appearance of mucoid strains of Streptococcus pyogenes with a continuing high incidence of rheumatic fever in Utah. Pediatrics, 113:e168-e172.
83. Wang H, Lottenberg R, and Boyle MDP. (1995). A role for fibrinogen in the streptokinase-dependent acquisition of plasmin (ogen) by group A streptococci. J Infect Dis, 171:85-92.
84. Wang B, Ruiz N, Pentland A, and Caparon M. (1997). Keratinocyte proinflammatory responses to adherent and non-adherent group A streptococci. Infect Immun, 65:2119-2126.
85. Wessels MR, Goldberg JB, Moses AE, and DiCesare TJ. (1994). Effects on virulence of mutations in a locus essential for hyaluronic acid capsule expression in group A streptococci. Infect Immun, 62:433-441.
86. Wessels MR, Moses AE, Goldberg JB, and DiCesare TJ. (1991). Hyaluronic acid capsule is a virulence factor for mucoid group A streptococci. Proc Natl Acad Sci U S A, 88:8317-8321.
87. Whitnack E and Beachey EH. (1982). Antiopsonic activity of fibrinogen bound to M protein on the surface of group A streptococci. J Clin Invest, 69:1042-1045.
88. Zabriskie JB. (1967). Mimetic relationships between group A streptococci and mammalian tissues. Adv Immunol, 7:147-188.
89. Zabriskie JB. (1985). Rheumatic fever: the interplay between host, genetics and microbe. Circulation, 71:1077-1086.
90. Zabriskie JB, Hsu KC, and Seegal BC. (1970). Heart-reactive antibody associated with rheumatic fever: characterization and diagnostic significance. Clin Exp Immunol, 7:147-159.